RANCHO CORDOVA, Calif. and LOS ANGELES and NEW DELHI, India, Aug. 8, 2013 (GLOBE NEWSWIRE) -- TotipotentRX Corporation ("TotiRX"), Fortis Memorial Research Institute ("Fortis") and ThermoGenesis Corp. (Nasdaq:KOOL) today announced the successful launch of their pediatric bone marrow transplant program at the Fortis-TotiRX Centre for Cellular Medicine in New Delhi, India. This week, the new program achieved its first 100-day survival milestone following an allogeneic bone marrow engraftment in a pediatric patient with aplastic anemia using a donor with ABO-incompatible bone marrow having a major blood group mismatch (Patient B+ve, Donor A+ve). The successful transplant was performed using the AXP ® AutoXpress ® Platform ("AXP"), and bone marrow software, a FDA and Drug Controller General of India ("DCGI") approved cell processing platform from ThermoGenesis Corp.
TotipotentRX And ThermoGenesis Announce Successful Launch Of Bone Marrow Transplant Program
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.